Under the LOI, SHINE will supply high quality n.c.a. Lu-177 to Affibody to support clinical research and development activities. This includes Affibody’s lead program ABY-271, a Lu-177-conjugated, HER2-targeted Affibody molecule currently under evaluation in a Phase 1 study in metastatic breast cancer, as well as additional Radioligand Therapy programs derived from Affibody’s proprietary technology platform.

In addition, the parties may explore an option to extend this arrangement to include commercial Lu-177 supply for ABY-271, should the program successfully progress to commercialization.

“The Letter of Intent with SHINE represents an important step in strengthening the supply chain for our Radioligand Therapy projects,” said David Bejker, CEO of Affibody. “Reliable access to high quality Lu 177 is essential as we advance ABY 271 through clinical development and continue to expand our Radioligand Therapy pipeline.”